LifeVantage Corp ( (LFVN) ) has released its Q3 earnings. Here is a breakdown of the information LifeVantage Corp presented to its investors.
LifeVantage Corporation, a leader in the health and wellness sector, specializes in nutrigenomics, offering products that enhance health at the cellular level. The company recently released its financial results for the third quarter of fiscal 2025, showcasing a robust performance with significant growth in revenue and profitability.
LifeVantage reported a 21.1% increase in revenue, reaching $58.4 million, driven by strong demand for its MindBody GLP-1 System™. The Americas region saw a remarkable 29.5% revenue increase, while Asia/Pacific & Europe experienced a decline, impacted by currency fluctuations. The company’s net income per diluted share doubled from the previous year, and adjusted EBITDA rose by 27% to $6.4 million.
The company focused on international expansion, launching new compensation plans and products in various countries, which contributed to its growth. Gross profit margins improved by 210 basis points, attributed to a favorable sales mix and reduced inventory expenses. Despite increased commissions and incentives, operating income more than doubled compared to the previous year.
Looking ahead, LifeVantage maintains a positive outlook, expecting fiscal year 2025 revenue between $228 million and $235 million, with adjusted EBITDA projected to range from $21 million to $24 million. The company remains committed to leveraging its unique position in the activation market to drive further growth.